Exercise performance in patients with post-acute sequelae of SARS-CoV-2 infection compared to patients with unexplained dyspnea

George A. Alba, David R. Ziehr, Jennifer N. Rouvina, Lida P. Hariri, Rachel S. Knipe, Benjamin D. Medoff, Kathryn A. Hibbert, Alyssa Kowal, Casey Hoenstine, Leo C. Ginns, Gregory D. Lewis, C. Corey Hardin

Department of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

ABSTRACT

Background: Dyspnea and exercise intolerance are commonly reported post-acute sequelae of SARS-CoV-2 infection (PASC), but routine diagnostic testing is often normal. Cardiopulmonary exercise testing (CPET) offers comprehensive assessment of dyspnea to characterize pulmonary PASC.

Methods: We performed a retrospective cohort study of CPET performed on patients reporting dyspnea and/or exercise intolerance following confirmed Covid-19 between August 1, 2020 and March 1, 2021, and compared them to age- and sex-matched patients with unexplained dyspnea referred for CPET at the same center in the pre-Covid-19 era.

Findings: Compared to matched unexplained dyspnea comparators, PASC patients shared similar medical comorbidities and subjective dyspnea at referral (mMRC score 1.6 ± 0.9 vs. 1.4 ± 0.9, P = 0.5). Fifteen (83.3%) PASC patients underwent high resolution computed tomography of the chest, of which half (46.7%) were normal, and 17 (94.4%) patients had normal findings. All patients underwent CPET, and 12 (67%) had normal findings. Compared to matched comparators, PASC patients had similar peak oxygen consumption, oxygen consumption at ventilatory anaerobic threshold, and ventilatory efficiency measured by the minute ventilation to carbon dioxide production (VE/VCO2) slope.

Interpretation: Despite prominent dyspnea, physiological abnormalities on CPET were mild across a range of initial Covid-19 severity and similar to matched comparators referred for dyspnea without antecedent SARS-CoV-2.

Funding: The project was supported by the NHLBI (R01HL113102, R01HL151841, U10HL110337, T32HL116275) and a KL2 award (5KL2TR002542-02) from Harvard Catalyst.

© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

Following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (Covid-19), a substantial proportion of patients describe a heterogenous constellation of persistent symptoms termed post-acute sequelae of SARS-CoV-2 infection (PASC) [1-5]. The exact incidence of PASC is unknown, but it is estimated that approximately 10% of all patients infected with SARS-CoV-2 experience symptoms lasting 1 month, with approximately 2.5% experiencing symptoms lasting beyond 3 months [5]. When applied to over 200 million infections globally, even this relatively low percentage represents a major challenge for the healthcare system [4].

Dyspnea and exercise intolerance are among the most commonly reported symptoms in patients with PASC [1-5], but the underlying physiological abnormalities causing these symptoms are unknown. Routine diagnostics, such as pulmonary function testing (PFT) and high-resolution computed tomography (HRCT) of the chest, are frequently normal in these patients, especially those with mild disease [6,7]. More precise diagnostic tests are therefore necessary to characterize the abnormalities associated with dyspnea and exercise intolerance in PASC. In addition, given the overwhelming scale of the Covid-19 pandemic, it will be important to differentiate symptoms of PASC from dyspnea due to other etiologies which may present coincident with, though not caused by, SARS-CoV-2 infection.

Cardiopulmonary exercise testing (CPET) affords an integrated assessment of cardiopulmonary, pulmonary vascular, systemic

https://doi.org/10.1016/j.eclinm.2021.101066

2589-5370 © 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Research in context

Evidence before this study

Cardiopulmonary exercise testing (CPET) affords an integrated assessment of multiple organ system contributions to exercise limitation and can yield clinically relevant physiological data for patients with multifactorial dyspnea, including survivors of viral pneumonia syndromes like SARS-CoV-2. We searched PubMed for articles since the outbreak of SARS-CoV-2 following January 1, 2020 up to April 13, 2021, using the terms “Cardiopulmonary exercise testing” or “CPET” or “Covid-19” or “SARS-CoV-2” and identified 3 cohort studies of patients undergoing CPET at the time of hospital discharge reporting abnormalities inclusive of ventilatory inefficiency, impaired heart rate recovery, and skeletal muscle deconditioning. However, few studies have characterized the results of CPET in patients with long-term persistent symptoms across a range of initial disease severity compared to a matched control population.

Added value of this study

We report comprehensive CPET results of the first 18 post-acute sequelae of SARS-CoV-2 infection patients referred by our institution’s Coronavirus Recovery Pulmonary clinic compared to age- and sex-matched comparators with unexplained dyspnea prior to the advent of the Covid-19 pandemic. Despite subjectively prominent dyspnea, physiological abnormalities on CPET were mild across a range of initial Covid-19 severity and were similar to those identified in patients with unexplained dyspnea in the pre-Covid-19 era.

Implications of all the available evidence

Cardiopulmonary exercise testing in patients with post-acute sequelae of SARS-CoV-2 infection reveals mild abnormalities which are similar to those identified in a matched group of dyspneic patients prior to the advent of COVID-19.

2. Methods

2.1. Study design

We performed a retrospective cohort study of adult outpatients referred by the Massachusetts General Hospital Coronavirus Recovery Pulmonary Clinic for comprehensive CPET via upright cycle ergometry between August 1, 2020 and March 13, 2021 with antecedent confirmed SARS-CoV-2 infection by nasopharyngeal polymerase chain reaction (PCR) and whose chief complaint was persistent dyspnea and/or exercise intolerance after recovery from acute SARS-CoV-2 infection. Patients referred for CPET who did not have confirmed SARS-CoV-2 infection by PCR were excluded from the PASC cohort. Additionally, patients with a submaximal effort defined by a respiratory exchange ratio (RER) < 1.0 were excluded (except PASC case 3 whose RER was 0.98 but had a peak oxygen consumption > 100% predicted). We identified age- and sex-matched comparator patients from a cohort comprised of all patients presenting for CPET in the same laboratory with a chief complaint of unexplained dyspnea and/or exercise intolerance between January 1, 2019 and January 1, 2020. All patients included in the comparator cohort did not have (1) any positive viral respiratory infection testing in the year prior to their CPET and (2) any mention of a clinical syndrome compatible with viral respiratory infection in the history of present illness documented at the time of their CPET.

The study was approved by the Mass General Brigham’s Institutional Review Board (Protocol #2010P001704) and informed consent was obtained from study participants.

2.2. Cardiopulmonary exercise testing and interpretation

Maximal effort CPET was performed on the same cycle ergometer (Lode, the Netherlands) and breath-by-breath gas exchange values were measured by the same metabolic cart (MedGraphics, St. Paul, MN). Data were analyzed according to previously published methods [11–13]. A maximal effort study is defined by a RER > 1.0. We consider a peak oxygen consumption (VO2) > 80% predicted to be normal whereas peak VO2 < 80% is abnormal. Oxygen pulse is defined as VO2 divided by heart rate and is equal to the product of stroke volume and arterial-mixed venous blood oxygen content difference (a measure of peripheral oxygen extraction) and is compared to predicted normal values based on age, sex, and height [14]. Ventilatory anaerobic threshold (VAT) was determined by the V-slope method [15], and in all the cases included here, we were able to determine VAT by the V-slope method. Ventilatory efficiency is defined by the minute ventilation to carbon dioxide production (VE/VCO2) slope which is assessed as the regression slopes of VE versus VCO2 from the start of exercise to the end of exercise. We additionally analyzed the pre-ventilatory anaerobic threshold (VAT) slope as the regression slope of VE versus VCO2 from the start of exercise to the end of exercise and the post-VAT slope as the regression slope of VE versus VCO2 from the VAT to the end of exercise [12].

2.3. Statistical analysis

All continuous variables were reported as median and interquartile range (IQR, 1st-3rd) or mean ± standard deviation where indicated. Categorical data were reported as numbers and percentages. Continuous variables were analyzed by Student’s t-test or Mann-Whitney U test according to their distributions based on the results of the Shapiro-Wilk test of normality. Categorical variables were analyzed by Fisher’s exact test where appropriate. No adjustment for multiple comparisons was made. No imputation was used for missing data. An α level of 0.05 was used for all hypothesis tests. All data analyses were performed using Stata (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP). Venn diagrams were created using BioVenn [16].

2.4. Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

3. Results

3.1. Baseline characteristics of the dyspnea cohorts

A total of 18 patients were included in the PASC and matched comparator cohorts, respectively. Demographics and clinical characteristics for the PASC and comparator patients are summarized in Table 1. In the PASC cohort (n = 18), the median age was 40.5 (IQR 34–57) and 12 patients (66.7%) were female. The comparator cohort
(n = 18) was matched to the PASC cohort based on age and sex. There were no statistically significant differences in the baseline demographics and comorbidities between the two groups, including baseline cardiopulmonary disease.

In the PASC cohort, 3 (16.7%) patients had pre-existing cardiac disease, 3 (16.7%) patients had pre-existing pulmonary disease, and 6 (33.3%) patients were obese with BMI ≥ 30. In all patients with baseline cardiopulmonary disease, the referring pulmonologists did not feel these diagnoses were sufficient to explain their new respiratory symptoms. The majority (83.3%) were never-smokers, and none were active tobacco smokers. All patients had confirmed SARS-CoV-2 infection by nasopharyngeal PCR. Three (16.7%) patients required hospitalization on a medical ward and 3 (16.7%) were critically ill in the intensive care unit (ICU) with acute respiratory distress syndrome (ARDS); the remainder were managed in the outpatient setting. All patients were referred to the Coronavirus Recovery Pulmonary Clinic with chief complaints of dyspnea and exercise intolerance. The mean modified Medical Research Council (mMRC) Dyspnea Scale score at time of CPET referral was similar between the PASC and matched comparator groups (1.6 ± 0.9 vs. 1.4 ± 0.9, P = 0.5). Fifteen (83.3%) patients underwent HRCT of the chest with prone and expiratory views: 7 (46.7%) were normal, 1 (6.7%) demonstrated isolated mosaicism and air-trapping on expiratory views, 6 (40%) demonstrated residual ground glass opacities, and 1 (6.7%) demonstrated a chronic organizing pneumonia pattern. Seventeen (94.4%) patients had full pulmonary function testing with spirometry, body plethysmography, and measurement of diffusing capacity of the lung for carbon monoxide (DLCO): 13 (76.5%) were normal, 1 (5.9%) demonstrated combined restriction and impaired DLCO, and 3 (17.6%) had an isolated impairment in DLCO. The overlap between normal and abnormal diagnostic studies is provided in Supplemental Figure 1.

### 3.2. Cardiopulmonary exercise testing results in the dyspnea cohorts

All patients underwent CPET on a cycle ergometer and 7 (39%) had concurrent first pass radionuclide ventriculography. CPET variables for the PASC and comparator patients are summarized in Table 2. In the PASC cohort, the median duration between index SARS-CoV-2 infection and CPET was 257.5 days (IQR 149–322). Twelve (67%) patients had normal CPET studies. Of the 6 (33%) patients with abnormal studies, 2 (33%) patients had an abnormal cardiovascular response with impaired cardiac output during exercise measured by ventriculography, 2 patients had an abnormal cardiovascular response with impaired cardiac output during exercise measured with spirometry, body plethysmography, and measurement of diffusing capacity of the lung for carbon monoxide (DLCO); 13 (76.5%) were normal, 1 (5.9%) demonstrated combined restriction and impaired DLCO, and 3 (17.6%) had an isolated impairment in DLCO. The overlap between normal and abnormal diagnostic studies is provided in Supplemental Figure 1.

### 3.3. Comparison of physiological variables across dyspnea cohorts

We next compared CPET parameters associated with deficits in specific organ systems across the two cohorts. Patients with PASC...
demonstrated similar resting heart rate (77.5 [IQR 74–84] vs. 73.5 [IQR 62–77.5] beats per minute, P = 0.05), peak workload (95 [IQR 76–110] vs. 91 [IQR 64–113]% predicted, P = 0.4), peak oxygen consumption (85.5 [IQR 69–100] vs. 85 [IQR 68–100]% predicted, P = 0.9), ventilatory anaerobic threshold (VAT) (134.5 [IQR 103–157] vs. 140 [IQR 125–164]% predicted, P = 0.5), oxygen pulse (95 [IQR 71–115] vs. 106 [IQR 102–110]% predicted, P = 0.3), and ventilatory efficiency as measured by the minute ventilation to carbon dioxide production (VE/VCO₂) slope (29.8 [IQR 27.4–32.7] vs. 28.4 [IQR 27.2–30.6], P = 0.15) (Fig. 1A-E).

We found that the partial pressure of end-tidal CO₂ (PETCO₂) at rest and at VAT was similar between the PASC and control groups, and the change in PETCO₂ between rest and at VAT was similar between the PASC and control groups (4.8 ± 3.2 vs. 6.2 ± 3.6, P = 0.2), suggesting a similar ventilatory response between the PASC and comparator patients. There was no evidence of a primary pulmonary mechanical limitation in either cohort with similar breathing reserve at peak exercise (Fig. 1F). To better understand the observed difference in ventilatory efficiency, we calculated the VE/VCO₂ slope before VAT (VE/VCO₂ pre-VAT slope), nadir VE/VCO₂ slope (VE/VCO₂ nadir), and VE/VCO₂ slope after VAT (VE/VCO₂ post-VAT slope). The VE/VCO₂ pre-VAT slope (Fig. 2A) and the VE/VCO₂ nadir were similar between groups; however, the PASC group demonstrated an increased VE/VCO₂ post-VAT slope (34.8 [IQR 32–37] vs. 32 [IQR 28–34], P = 0.04) (Fig. 2B).

### 4. Discussion

We characterized dyspnea and exercise limitation in 18 patients with PASC following confirmed SARS-CoV-2 infection who were referred to a dedicated pulmonary PASC clinic. The majority of patients in our cohort demonstrated normal objective cardiopulmonary testing prior to CPET. The most common abnormalities detected included ground glass opacities on cross-sectional thoracic imaging and impairments in DlCO. Despite subjectively prominent dyspnea and exercise limitation, physiological abnormalities on CPET were mild across a range of initial COVID-19 severity. The most prominent abnormalities were observed in the two ARDS survivors, both of whom had cardiovascular limitations: one with impaired cardiac output due to chronicotropin incompetence and the other with residual cardiomyopathy.

Other investigators have observed that hyperventilation and/or dysregulated ventilatory control could underlie the debilitating cardiorespiratory symptoms in PASC [17]. However, we did not observe a difference in ventilatory efficiency in patients with PASC compared with matched comparators with unexplained dyspnea. Ventilatory efficiency is known to be altered in several cardiorespiratory diseases and may represent either (1) hyperventilation with relatively preserved dead space (normal Vd/Vt), (2) increased Vd/Vt, which results in an exaggerated increase in minute ventilation in response to increasing metabolic demand, or (3) some combination of the two [18,19]. Elevated Vd/Vt leading to decreased ventilatory efficiency is associated with pulmonary vascular disease [20,21], but in our PASC cohort both the VE/VCO₂ slope and the peak VO₂ were in the normal range. In addition, there was normal augmentation of the PETCO₂ and no evidence of arterial oxygen desaturation with exercise, all of which argue against substantial pulmonary vascular disease in this cohort [22].

Differences in VE/VCO₂ slope pre- and post-VAT are prognostically meaningful in both cohorts of patients with heart failure with preserved ejection fraction and in an at-risk comparator population [11,12]. Increased early exercise VE/VCO₂ slope or nadir VE/VCO₂ (i.e., during submaximal exercise) is associated with increased cardiovascular risk factors, decreased cardiovascular performance on CPET, and increased death and adverse cardiovascular events [11,12]. In addition, pre-VAT VE/VCO₂ slope and overall VE/VCO₂ slope are potentially sensitive to early exercise hyperventilation [12]. Increased late exercise VE/VCO₂ slope (i.e., during maximal exercise) is associated with decreased cardiovascular risk factors and increased cardiovascular performance and may, in fact, reflect higher physical fitness and better lung function [11]. Our findings of overall normal ventilatory efficiency, similar pre-VAT VE/VCO₂ slope between PASC and non-PASC patients with unexplained dyspnea, similar nadir VE/ VCO₂, and increased post-VAT VE/VCO₂ slope in PASC patients all argue against pulmonary vascular disease or a hyperventilatory response to exercise as a distinguishing feature of PASC in our cohort.

The most notable finding in our study is the remarkable similarity of CPET across patients with PASC and those presenting with unexplained dyspnea in the pre-COVID-19 era. Similar cohort studies of

### Table 2: Cardiopulmonary exercise test results in PASC and comparator cohorts.

| Variable                      | PASC Cohort (n = 18) | Control Cohort (n = 18) | P-value |
|-------------------------------|----------------------|-------------------------|---------|
| Time between infection and CPET (days) | 258 (IQR 149–322) | N/A                     | N/A     |
| Hemoglobin (g/dL)            | 13.9 (IQR 12.5–14.4) | 14 (IQR 13.1–14.9)      | 0.5^    |
| Respiratory exchange ratio (RER) | 1.24 (IQR 1.17–1.25) | 1.16 (IQR 1.12–1.2)    | 0.04^   |
| Resting heart rate (bpm)    | 77.5 (IQR 74–84)     | 73.5 (IQR 62–77.5)      | 0.05^   |
| Peak heart rate (bpm)       | 162 (IQR 142–171)    | 138 (IQR 132–157)       | 0.02^   |
| Peak heart rate (% predicted by age) | 91 (IQR 82–95) | 84 (IQR 69–91)          | 0.04^   |
| Heart rate recovery at 1 min (bpm) | 18.2 ± 8.3 | 21.2 ± 10                | 0.4     |
| Work (Watts)                 | 133 (IQR 123–182)    | 145 (IQR 76–184)        | 0.4     |
| Work (% predicted)           | 95 (IQR 76–110)      | 91 (IQR 64–113)         | 0.4     |
| Metabolic equivalents (METS) | 5.4 (IQR 4.5–8)      | 5.6 (IQR 4.2–6.8)       | 1.0     |
| METS (% predicted)           | 83.5 (IQR 64–101)    | 85 (IQR 66–103)         | 0.9     |
| Peak oxygen consumption (VO₂) | 20 (IQR 16–27)      | 19.5 (IQR 16–23.5)      | 0.8     |
| Peak VO₂ (% predicted)       | 85.5 (IQR 69–100)    | 85 (IQR 68–100)         | 0.9     |
| Ventilator anaerobic threshold (VAT) | 12.4 (IQR 10.5–14.7) | 12.9 (IQR 10.3–15.5)     | 0.8     |
| VAT (% predicted)            | 134.5 (IQR 103–157) | 140 (IQR 125–164)       | 0.5     |
| Oxygen (O₂) pulse (% predicted) | 10.15 (IQR 8.3–13.2) | 11.65 (IQR 10.1–13.5) | 0.5     |
| O₂ pulse ( % predicted)      | 95 (IQR 71–115)      | 106 (IQR 102–110)       | 0.3     |
| VE/VCO₂ Slope (normal -33)   | 29.8 (IQR 27.4–32.7) | 28.4 (IQR 27.2–30.6)     | 0.15    |
| Nadir VE/VCO₂ Slope          | 1.8 (IQR 1.1–3)      | 2.3 (IQR 1.5–3.5)       | 0.3     |
| Pre-VAT VE/VCO₂ Slope        | 26.6 (IQR 24–29)     | 25.8 (IQR 24–27)        | 0.6     |
| Post-VAT VE/VCO₂ Slope       | 34.8 (IQR 32–37)     | 32.0 (IQR 28–34)        | 0.04    |
| PETCO₂ Rest (mm Hg, normal -36) | 34.5 (IQR 32–37) | 32 (IQR 32–36)          | 0.5     |
| PETCO₂ VAT (mm Hg, normal -40) | 38 (IQR 36–43) | 39 (IQR 37–41)          | 0.5     |
| ∆ PETCO₂ (mm Hg)             | 4.8 ± 3.2            | 6.2 ± 3.6                | 0.3     |
| Breathing Reserve (% predicted) | 39 (IQR 37–41) | 37.5 (IQR 27–54)        | 0.3     |

* RER, respiratory exchange ratio (ratio of carbon dioxide produced and oxygen consumed, whereby RER > 1.0 indicates a maximum effort study); VO₂, oxygen consumption; MET, metabolic equivalents (one MET = 3.5 ml/kg/min of VO₂, the approximate unit of resting oxygen uptake); VAT, ventilatory anaerobic threshold (as determined by the V-slope method); oxygen (O₂) pulse = VO₂/heart rate, the product of stroke volume and arterial-mixed venous blood oxygen content difference; VE/VCO₂ slope, ventilatory efficiency (reflects pulmonary ventilation-perfusion matching and ventilatory drive); PETCO₂, partial pressure of end-tidal carbon dioxide (should increase by 3–6 mm Hg from rest to VAT); breathing reserve (difference between estimated maximum voluntary ventilation and minute ventilation achieved).

* Student’s t-test.
* Mann–Whitney U test.
patients with PASC have evaluated patients within a 3-month time point following initial SARS-CoV-2 infection and have noted abnormalities in peak VO2, ventilatory efficiency, peripheral extraction, and overall conditioning [17,22-24]. In contrast, our cohort was evaluated later in their recovery, with a median of 258 days (range 64 to 62 days) following their index infection. Despite prominent symptoms of persistent dyspnea and exercise intolerance, we find few differences compared to the matched unexplained dyspnea. However, we do observe that the percent predicted for peak workload and metabolic equivalents achieved are at the low end of the normal range. Additionally, we see a greater proportion of PASC patients with an abnormal CPET without baseline cardiopulmonary disease (Supplemental Figure 2), the majority characterized by a decreased O2 pulse. In those patients in our cohort who had both a decreased oxygen pulse and underwent an additional measure of cardiac function (i.e., ventriculography or invasive CPET), cardiac function was normal, suggestive of a peripheral limitation to exercise as may be seen in impaired skeletal muscle oxygen extraction. We conclude that dyspnea in patients with PASC is due to heterogenous pathophysiology, not all necessarily directly related to antecedent SARS-CoV-2 infection. Importantly, even in patients for whom significant time has elapsed since their index illness, PASC is characterized by significant persistent dyspnea. Careful phenotyping, inclusive of CPET, will be needed in order to appropriately guide treatment.

Fig. 1. Patients with PASC have similar exercise performance as non-PASC patients with unexplained dyspnea. Compared to age- and sex-matched comparators with unexplained dyspnea (UD), patients with PASC (post-acute sequelae of SARS-CoV-2 infection) demonstrate (A) similar peak work (W, Watts), (B) increased peak heart rate (HR, beats per minute), (C) similar peak oxygen consumption (VO2, mL/kg/min), (D) similar VO2 at ventilatory anaerobic threshold (VAT), (E) similar minute ventilation to carbon dioxide production (VE/VCO2) slope, and (F) similar breathing reserve (%). Boxes depict the median with interquartile range and whiskers indicate minimum and maximum values. * signifies P<0.05.

Fig. 2. Patients with PASC demonstrate ventilatory inefficiency post-ventilatory anaerobic threshold. Compared to age- and sex-matched comparators with unexplained dyspnea (UD Cohort), patients with PASC (post-acute sequelae of SARS-CoV-2 infection) demonstrate (A) similar pre-ventilatory anaerobic threshold (VAT) minute ventilation to carbon dioxide production (VE/VCO2) slope (26.6 vs. 25.8, P = 0.6) but (B) increased post-VAT VE/VCO2 slope (34.8 vs. 32, P = 0.04). VE, minute ventilation (L/min); VCO2, carbon dioxide production (L/min).
There are important limitations to this preliminary prospective study that preclude generalizability. This includes our small sample size, single institution experience, and inherent referral bias. Moreover, communities disproportionately impacted by Covid-19 are not yet fully represented in this sample [25]. It is also possible that CPET findings would be different if testing were conducted closer to the time of Covid-19 diagnosis; however, our patients remained significantly symptomatic at the time of CPET. Nonetheless, given the prevalent impact of PASC, early reports of cardiopulmonary phenotyping suggest that pulmonary PASC is heterogeneous in nature. We also find that the physiological abnormalities associated with dyspnea and exercise intolerance in the PASC population may be undetectable by standard diagnostic testing. Future studies of dyspnea and exercise limitation in PASC will require more sensitive, non-standard diagnostic testing to fully uncover the underlying pathobiology, including comprehensive CPET.

Declaration of Competing Interest

LPH receives consulting fees from Plaint Therapeutics and Boehringer Ingelheim and serves on the medical advisory board Boehringer Ingelheim, all unrelated to the content of this manuscript. BDM is a data safety monitoring board member for a clinical trial (Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Efficacy of SIR1 – 365 in Patients with Severe COVID-19) funded by Sironax, USA, unrelated to the content of this manuscript; received payment from Abbvie for providing a presentation on severe COVID-19. GDL serves on the steering committee for clinical trials related to CPET for Amgen, AstraZeneca, Cycloergion, and Cytokinetics, all unrelated to the content of this manuscript; and Cardiopulmonary Exercise Testing Core Laboratory Projects with NHLBI, Amgen, AstraZeneca, Cycloergion, Cytokinetics, Applied Therapeutics, and Abbott, that are not directly related to this work.

Acknowledgments

We thank all our colleagues on the front lines who helped cared for patients during unprecedented circumstances.

Author contributions

GAA, LCG, DRZ, GDL, and CCH contributed to the concept or design of the study. GAA, DRZ, JNR, AK, CH, and CCH contributed to data acquisition. GAA, DRZ, LCG, GDL, and CCH were involved in the analysis and interpretation of the data. All authors were involved in drafting or critically revising the manuscript, and all authors approved the final version and are accountable for the accuracy and integrity of the manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. At least three authors (GAA, DRZ, and CCH) have accessed and verified the data.

Funding

The project was supported by the NHLBI (R01HL131029, R01HL151841, U01HL103377, T32HL116275) and a K22 award (5KL2TR002542-02) from Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, NIH Award KL2 TR002542). The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the National Institutes of Health.

Data sharing statement

Individual de-identified patient data have been made available in the Appendix of this manuscript.

Supplementary materials

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.eclinm.2021.101066.

References

[1] Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA 2020;324(5):603–5 Aug 11.

[2] Carvalho-Schneider C, Laurent E, Lemaignan A. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect 2021;27 (2):258–63 Feb.

[3] Huang C, Huang L, Wang Y, Li X, Ren L. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397(10270):220– 32 Jan 16.

[4] Nalbandian A, Sehgal K, Gupta A. Post-acute COVID-19 syndrome. Nat Med 2021;27(4):601–15 Apr.

[5] Sudre CH, Murray B, Varavarsky T. Attributes and predictors of long COVID. Nat Med 2021;27(4):626–31 Apr.

[6] Guler SA, Ehner L, Bergelmann C. Pulmonary function and radiological features four months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. Eur Respir J 2021 Jan 8;2003690.

[7] Lerum TV, Aalakken TM, Braanstad E. Dyspnoea, lung function and CT findings three months after hospital admission for COVID-19. Eur Respir J 2020 Dec 10;2003488.

[8] Benington S, McWilliams D, Eddleston J. Exercise testing in survivors of intensive care— is there a role for cardiopulmonary exercise testing? J Crit Care 2012;27(1):80–94 Feb.

[9] Chan XL, Lam JY, Wah-Shing L. Exercise limitation in survivors of severe acute respiratory syndrome (SARS). Chest 2004;124(4):737S. Oct.

[10] Neff TA, Stocker R, Frey H-R. Long-term assessment of lung function in survivors of severe ARDS. Chest 2003;123(3):845–53 Mar.

[11] Nayar M, Shah RV, Miller PE. Metabolic architecture of acute exercise response in middle-aged adults in the community. Circulation 2020;142(20):1905–24 Nov 17.

[12] Nayar M, Xanthakis V, Tanguay M. Clinical and hemodynamic associations and prognostic implications of ventilatory efficiency in patients with preserved left ventricular systolic function. Circ Heart Fail 2020;13(5) May006729.

[13] Shah RV, Schoenike MW, Armentol de la Hoz MA. Metabolic cost of exercise initiation in patients with heart failure with preserved ejection fraction vs community-dwelling adults. JAMA Cardiol 2021 Mar 17;2(3):258.

[14] Hansen JE, Sue DY, Wasserman K. Predicted values for clinical exercise testing. Am Rev Respir Dis 1984;129:549–52 Pt 2.

[15] Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol 1986;60(6):2020–7.

[16] Hulsen T, de Vlieg J, Algouma W. BioVenn - a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. BMC Genomics 2008;9:488.

[17] Motiejunaitis J, Balagyn P, Arnoux F. Hyperventilation: a possible explanation for long-lasting exercise intolerance in mild COVID-19 survivors? Front Physiol 2021:11:614590 Jan 18.

[18] Phillips DB, Collins SE, Stickland MK. Measurement and interpretation of exercise efficiency in patients with preserved left ventricular systolic function. Front Physiol 2020;11:659. Jun 25.

[19] Faisal A, Alghamdi BJ, Ciavaglia CE. Common mechanisms of dyspnea in chronic intermittent and obstructive lung disorders. Am J Respir Crit Care Med 2016;193 (3):299–309 Feb 1.

[20] Lewis GD, Shah RV, Pappagianopoulos PP. Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone. Circ Heart Fail 2008;1:227–33.

[21] Sun XG, Hansen JE, Oudiz RJ. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 2001;104(4):429–35 Jul 24.

[22] Baratto C, Caravita S, Faini A. Impact of COVID-19 on exercise pathophysiology. A combined cardiopulmonary and echocardiographic exercise study. J Appl Physiol 2021 Mar 25: doi:10.1152/japplphysiol.00710.2020.

[23] Kaman B, Caspar MP, Tunnicliffe EM. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine 2021;31:100683 Jan 7. doi: 10.1016/j.eclinm.2021.100683.

[24] Rinaldo RF, Mondini M, Parazzini EM. Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors. Eur Resp J 2021 May 62100870. doi: 10.1183/13993003.00870-2021.

[25] Ziehr DR, Alladina J, Petri CK. Respiratory pathobiology of mechanically ventilated patients with COVID-19: a cohort study. Am J Respir Crit Care Med 2020;201(12):1560–4 Jun 15.